Dave R Miller

8486423, Jul 16, 2013

Aug 21, 2008

12/196154

Chris Brough - Austin TX, US
James W. McGinity - Austin TX, US
Dave A. Miller - Austin TX, US
James DiNunzio - Austin TX, US
Robert O. Williams - Austin TX, US

Board of Regents, The University of Texas System - Austin TX
Integrico Composites, Inc. - Temple TX

A61K 9/00
A61K 31/50
A01N 43/58

424400, 514247

Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can be further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.

20080274194, Nov 6, 2008

Nov 9, 2005

11/718620

Dave A. Miller - Austin TX, US
Jason T. McConville - Austin TX, US
James W. McGinity - Austin TX, US
Robert O. Williams - Austin TX, US

BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

A61K 9/14
A61P 43/00

424489

A hot-melt extruded composition having finely divided drug-containing particles dispersed within a polymeric and/or lipophyllic carrier matrix is provided. The carrier softens or melts during hot-melt extrusion but it does not dissolve the drug-containing particles during extrusion. As a result, a majority or at least 90% wt. of the drug-containing particles in the extrudate are deaggregated during extrusion into essentially primary crystalline and/or amorphous particles. PEO is a suitable carrier material for drugs insoluble in the solid state in this carrier. Various functional excipients can be included in the carrier system to stabilize the particle size and physical state of the drug substance in either a crystalline and/or amorphous state. The carrier system is comprised of at least one thermal binder, and may also contain various functional excipients, such as: super-disintegrants, antioxidants, surfactants, wetting agents, stabilizing agents, retardants, or similar functional excipients. A hydrophilic polymer, such as hydroxypropyl methylcellulose (HPMC E15), polyvinyl alcohol (PVA), or poloxamer, and/or a surfactant, such as sodium lauryl sulfate (SLS), can be included in the composition. A process for preparing the extrudate is conducted at a temperature approximating or above the softening or melting temperature of the matrix and below the point of solubilization of drug-containing particles in the carrier system, and below the recrystallization point in the case of amorphous fine drug particles.

20120114751, May 10, 2012

Nov 8, 2011

13/291387

Andreas Leiminer - Grenzach-Wyhlen, DE
Kai Lindenstruth - Berlin, DE
Dave Alan Miller - Round Rock TX, US
Emmanuel Scheubel - Sierentz, FR
Navnit Hargovindas Shah - Clifton NJ, US

A61K 31/407
A61K 9/48
A61P 31/14
A61K 9/28

424463, 514411, 424474

The present invention relates to a granular pharmaceutical composition comprising an HCV protease inhibitor and at least one poloxamer.

20130331314, Dec 12, 2013

Aug 23, 2013

13/974243

Kai Lindenstruth - Berlin, DE
Dave Alan Miller - Round Rock TX, US
Emmanuel Scheubel - Sierentz, FR
Navnit Hargovindas Shah - Clifton NJ, US

Hoffmann-La Roche Inc. - Nutley NJ

A61K 47/34
A61K 38/06

514 43

The present invention relates to a granular pharmaceutical composition comprising an HCV protease inhibitor and at least one poloxamer.

20140039031, Feb 6, 2014

Feb 23, 2012

14/001098

Chris Brough - Austin TX, US
James W. McGinity - Austin TX, US
Dave A. Miller - Round Rock TX, US
Justin Hughey - Hightstown NJ, US
Ryan Bennett - Austin TX, US

Dispersol Technologies. LLC - Georgetown TX
Board of Regents, The University of Texas System - Austin TX

A61K 31/404
A61K 31/12
A61K 31/19

514414, 514557, 514679

The present disclosure is directed to compositions and methods for formulating a pharmaceutical dosage form by forming a composition comprising acetyl-11-keto-β-boswellic acid, diindolylmethane, or curcumin with one or more pharmaceutically acceptable excipients for enhanced solubility to increase bioavailability and improve therapeutic efficacy. The composition can be processed by thermo-kinetic compounding along with conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.

20220401579, Dec 22, 2022

Sep 24, 2020

17/777102

- Georgetown TX, US
- Austin TX, US
Dave MILLER - Georgetown TX, US
Angela SPANGENBERG - Austin TX, US
Daniel J. ELLENBERGER - Cedar Park TX, US

DISPERSOL TECHNOLOGIES, LLC - Georgetown TX
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

A61K 47/69
A61K 31/496
A61K 31/44
A61K 31/5377

Pharmaceutical formulations including an inclusion complex of an API with a cyclic oligomer, and methods of forming such pharmaceutical formulations are described.

20210128536, May 6, 2021

Oct 8, 2020

17/065664

- Georgetown TX, US
- Austin TX, US
Daniel Alan DAVIS - Austin TX, US
Dave A. MILLER - Georgetown TX, US

DISPERSOL TECHNOLOGIES, LLC - Georgetown TX
BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM - Austin TX

A61K 31/444
A61K 47/38
A61K 47/32
A61K 9/16
A61K 9/00
A61K 31/496
A61K 31/136
A61K 31/704
A61K 31/475
A61K 31/167
A61K 31/5415

The present disclosure relates to pharmaceutical formulations including a weakly basic drug and an ionic polymer in an amorphous solid dispersion, as well as methods of forming such pharmaceutical formulations, and methods of administering such pharmaceutical formulations.

20200261473, Aug 20, 2020

May 5, 2020

16/866676

- Austin TX, US
- Georgetown TX, US
Dave A. MILLER - Round Rock TX, US
James C. DINUNZIO - Bridgewater NJ, US

BOARD OF REGENTS, THE UNIVERISTY OF TEXAS SYSTEM - Austin TX
DISPERSOL TECHNOLOGIES, LLC - Georgetown TX

A61K 31/573
A61K 47/38
A61K 47/32
A61K 31/496
A61K 31/343
A61J 3/10
A61J 3/07
A61J 3/00
A61K 9/20
A61K 9/16
A61K 9/14

Compositions and methods for making a pharmaceutical dosage form include making a pharmaceutical composition that includes one or more active pharmaceutical ingredients (API) with one or more pharmaceutically acceptable excipients by thermokinetic compounding into a composite. Compositions and methods of preprocessing a composite comprising one or more APIs with one or more excipients include thermokinetic compounding, comprising thermokinetic processing the APIs with the excipients into a composite, wherein the composite can he further processed by conventional methods known in the art, such as hot melt extrusion, melt granulation, compression molding, tablet compression, capsule filling, film-coating, or injection molding.